Price T Rowe Associates Inc Alvotech Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Alvotech stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,401,421 shares of ALVO stock, worth $14.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,401,421Holding current value
$14.4 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALVO
# of Institutions
50Shares Held
15.8MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.19MShares$43.1 Million0.0% of portfolio
-
Bracebridge Capital, LLC2.71MShares$27.8 Million20.4% of portfolio
-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca1.87MShares$19.2 Million0.54% of portfolio
-
Littlejohn & CO LLC1.32MShares$13.6 Million6.46% of portfolio
-
Point State Capital LP New York, NY1.17MShares$12.1 Million0.18% of portfolio
About Alvotech
- Ticker ALVO
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 248,650,000
- Market Cap $2.56B
- Description
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...